Fusako Sera
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fusako Sera has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
Yasushi Sakata
Department of Cardiovascular Medicine, The University of Osaka Graduate School of Medicine , 2-15 Yamadaoka, Suita 565-0871
5 shared publicationsTomohito Ohtani
Department of Cardiovascular Medicine, The University of Osaka Graduate School of Medicine , 2-15 Yamadaoka, Suita 565-0871
4 shared publications- Tomohito Ohtani
Department of Cardiovascular Medicine, The University of Osaka Graduate School of Medicine, Suita, Japan
4 shared publications - Yasushi Sakata
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
4 shared publications Kei Nakamoto
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan
3 shared publicationsYasuhiro Akazawa
Department of Cardiovascular Medicine, The University of Osaka Graduate School of Medicine , 2-15 Yamadaoka, Suita 565-0871
3 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (17)
Association of Summed Rest Score on Technetium‐99m Sestamibi With Exercise Capacity and Incident Adverse Outcomes in Hospitalized Patients With Nonischemic Cardiomyopathy: A Retrospective Analysis
Background: In nonischemic cardiomyopathy, the clinical relevance of decreased resting myocardial technetium‐99m sestamibi ( 99m Tc‐MIBI) uptake regarding exercise capacity and clinical outcomes remains incompletely understood. We investigated whether decreased 99m Tc‐MIBI uptake is associated with impaired exercise capacity and adverse clinical outcomes in nonischemic cardiomyopathy. Methods: We retrospectively analyzed 182 patients (mean age 51.4±14.0 years; 27% female) with nonischemic cardiomyopathy and left ventricular ejection fraction 99m Tc‐MIBI scintigraphy and cardiopulmonary exercise testing from 2016 to 2023. Myocardial uptake of 99m Tc‐MIBI was evaluated using the summed rest score (SRS). Exercise capacity was assessed by percentage of predicted peak oxygen consumption (PPVO 2 ), with ≤60% defining impairment. Results: Seventy‐four patients (41%) had PPVO 2 ≤60% and higher SRS (median: 12 versus 8; P < 0.001). Higher SRS remained significantly associated with PPVO 2 ≤60% after adjustment for relevant clinical covariates, including brain natriuretic peptide level, left ventricular ejection fraction, and heart failure duration. Over a median follow‐up of 807 days, 23 patients (13%) experienced the composite outcome of all‐cause death, ventricular assist device implantation, or heart transplantation. Higher SRS was associated with composite outcomes after adjusting for PPVO 2 ≤60%. Among the 4 groups stratified by median SRS of 9 and PPVO 2 of 60%, patients with high SRS and low PPVO 2 had the highest incidence of adverse events. Conclusions: Decreased myocardial 99m Tc‐MIBI uptake was associated with impaired exercise capacity and adverse outcomes in patients with nonischemic cardiomyopathy. Our findings suggest that myocardial injury assessment using 99m Tc‐MIBI scintigraphy may provide prognostic information complementary to exercise capacity.
- 1 September 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (17)
Open AccessAssociation of Summed Rest Score on Technetium‐99m Sestamibi With Exercise Capacity and Incident Adverse Outcomes in Hospitalized Patients With Nonischemic Cardiomyopathy: A Retrospective Analysis
Background: In nonischemic cardiomyopathy, the clinical relevance of decreased resting myocardial technetium‐99m sestamibi ( 99m Tc‐MIBI) uptake regarding exercise capacity and clinical outcomes remains incompletely understood. We investigated whether decreased 99m Tc‐MIBI uptake is associated with impaired exercise capacity and adverse clinical outcomes in nonischemic cardiomyopathy. Methods: We retrospectively analyzed 182 patients (mean age 51.4±14.0 years; 27% female) with nonischemic cardiomyopathy and left ventricular ejection fraction 99m Tc‐MIBI scintigraphy and cardiopulmonary exercise testing from 2016 to 2023. Myocardial uptake of 99m Tc‐MIBI was evaluated using the summed rest score (SRS). Exercise capacity was assessed by percentage of predicted peak oxygen consumption (PPVO 2 ), with ≤60% defining impairment. Results: Seventy‐four patients (41%) had PPVO 2 ≤60% and higher SRS (median: 12 versus 8; P < 0.001). Higher SRS remained significantly associated with PPVO 2 ≤60% after adjustment for relevant clinical covariates, including brain natriuretic peptide level, left ventricular ejection fraction, and heart failure duration. Over a median follow‐up of 807 days, 23 patients (13%) experienced the composite outcome of all‐cause death, ventricular assist device implantation, or heart transplantation. Higher SRS was associated with composite outcomes after adjusting for PPVO 2 ≤60%. Among the 4 groups stratified by median SRS of 9 and PPVO 2 of 60%, patients with high SRS and low PPVO 2 had the highest incidence of adverse events. Conclusions: Decreased myocardial 99m Tc‐MIBI uptake was associated with impaired exercise capacity and adverse outcomes in patients with nonischemic cardiomyopathy. Our findings suggest that myocardial injury assessment using 99m Tc‐MIBI scintigraphy may provide prognostic information complementary to exercise capacity.
- Open Access
- 7 April 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (7) , e045155
Prognostic Impact of Elevated Pulmonary Vascular Resistance in Group 2 Pulmonary Hypertension: Insights From a Japanese Multicenter Registry
Background: Group 2 pulmonary hypertension ( PH ), defined as PH caused due to left heart disease, remains a challenging condition. However, its prognostic impact and implications for emerging therapies are unclear. We aimed to evaluate the real‐world relationship between pulmonary vascular resistance ( PVR ) and prognosis in Group 2 PH and assess the efficacy of emerging therapies. Methods: Two prospective registries supported by Japanese PH societies were analyzed: a current (2018–2024; n=563) and a previous (2012–2016; n=425) registry. The composite end points were hospitalization for heart failure, all‐cause death, ventricular assist device implantation, or cardiac transplantation. Results: Stratified analyses using propensity score–matched data demonstrated a significant association between PVR >3 Wood units and prognosis in patients with Group 2 PH (6‐year event‐free rates, PVR > 3 Wood units versus PVR ≦ 3 Wood units, previous registry: 72.9% versus 61.4%; current registry: 75.2% versus 55.4%). Consistent patterns were observed in both heart failure with reduced ejection fraction and heart failure with preserved ejection fraction subgroups. The use of SGLT2 (sodium‐glucose cotransporter‐2) inhibitors in the current registry was associated with improved outcomes in patients with elevated PVR , showing event‐free rates of 73.8% versus 35.5% in those without treatment. Among multivariate analyses including major treatment options, SGLT2 inhibitor treatment exhibited significant associations with improvement of composite end points. Conclusions: Elevated PVR (>3 Wood units) identified a high‐risk subset of patients with Group 2 PH . The association between the use of SGLT2 inhibitors and better outcomes suggests a potential therapeutic role that warrants further investigation through controlled studies.
- 7 April 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (7) , e045155
Open AccessPrognostic Impact of Elevated Pulmonary Vascular Resistance in Group 2 Pulmonary Hypertension: Insights From a Japanese Multicenter Registry
Background: Group 2 pulmonary hypertension ( PH ), defined as PH caused due to left heart disease, remains a challenging condition. However, its prognostic impact and implications for emerging therapies are unclear. We aimed to evaluate the real‐world relationship between pulmonary vascular resistance ( PVR ) and prognosis in Group 2 PH and assess the efficacy of emerging therapies. Methods: Two prospective registries supported by Japanese PH societies were analyzed: a current (2018–2024; n=563) and a previous (2012–2016; n=425) registry. The composite end points were hospitalization for heart failure, all‐cause death, ventricular assist device implantation, or cardiac transplantation. Results: Stratified analyses using propensity score–matched data demonstrated a significant association between PVR >3 Wood units and prognosis in patients with Group 2 PH (6‐year event‐free rates, PVR > 3 Wood units versus PVR ≦ 3 Wood units, previous registry: 72.9% versus 61.4%; current registry: 75.2% versus 55.4%). Consistent patterns were observed in both heart failure with reduced ejection fraction and heart failure with preserved ejection fraction subgroups. The use of SGLT2 (sodium‐glucose cotransporter‐2) inhibitors in the current registry was associated with improved outcomes in patients with elevated PVR , showing event‐free rates of 73.8% versus 35.5% in those without treatment. Among multivariate analyses including major treatment options, SGLT2 inhibitor treatment exhibited significant associations with improvement of composite end points. Conclusions: Elevated PVR (>3 Wood units) identified a high‐risk subset of patients with Group 2 PH . The association between the use of SGLT2 inhibitors and better outcomes suggests a potential therapeutic role that warrants further investigation through controlled studies.
- 19 July 2025
- Published by Springer Nature
- p. 143-149
Medical and Surgical Management of Adult Congenital Heart Disease
- 19 July 2025
- Published by Springer Nature
- p. 143-149
Medical and Surgical Management of Adult Congenital Heart Disease
- 19 July 2025
- Published by Springer Nature
- p. 151-158
Social Reintegration in Survivors of Pediatric Heart Transplantation
- 19 July 2025
- Published by Springer Nature
- p. 151-158
Social Reintegration in Survivors of Pediatric Heart Transplantation
- 19 July 2025
- Published by Springer Nature
- p. 135-141
Therapeutic Strategies for Advanced Heart Failure Related to Heart Transplantation
- 19 July 2025
- Published by Springer Nature
- p. 135-141
Therapeutic Strategies for Advanced Heart Failure Related to Heart Transplantation
- Open Access
- 28 April 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 9 (5) , ytaf213
Three episodes of recurrent Takotsubo syndrome pre- and post-heart transplantation: a case report
Background: Cardiac sympathetic hyperactivity may be implicated in the pathogenesis of Takotsubo syndrome (TTS). With complete denervation of a transplanted heart, the recipient heart is less susceptible to sympathetic hyperactivity. We report a rare case of recurrent TTS in a heart transplant recipient from a donor with TTS. Iodine-123 meta-iodobenzylguanidine (123I-MIBG) scintigraphy results for evaluating sympathetic activity are presented. Case Summary: A 46-year-old woman underwent heart transplantation for dilated phase of hypertrophic cardiomyopathy following recurrent cerebral haemorrhage complications after left ventricular assist device therapy 2 years prior. The donor heart exhibited a transient mildly reduced left ventricular ejection fraction suggestive of TTS. Four years post-transplantation, she was admitted with difficulty breathing, and echocardiography showed decreased biventricular apical wall motion. During her treatment course, wall motion improved spontaneously, and giant negative T waves were observed on electrocardiography (ECG). Coronary computed tomography and endomyocardial biopsy findings were normal, and a diagnosis of TTS was made. Approximately 5 years post-transplantation, she was readmitted with difficulty breathing, and echocardiography showed akinesis of the mid-to-apical biventricular wall. Wall motion normalized within a few days, and ECG showed typical giant negative T waves, consistent with TTS. 123I-MIBG scintigraphy taken prior to discharge and 6 months later showed minimal myocardial uptake in the basal anterior wall, indicating insufficient sympathetic reinnervation. Discussion: Recurrent TTS in a denervated heart suggests the possibility of other underlying mechanisms besides cardiac sympathetic hyperactivity. This case highlights potential TTS development in transplant recipients from donors with TTS, underlining the need for close monitoring.
- 28 April 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 9 (5) , ytaf213
Open AccessThree episodes of recurrent Takotsubo syndrome pre- and post-heart transplantation: a case report
Background: Cardiac sympathetic hyperactivity may be implicated in the pathogenesis of Takotsubo syndrome (TTS). With complete denervation of a transplanted heart, the recipient heart is less susceptible to sympathetic hyperactivity. We report a rare case of recurrent TTS in a heart transplant recipient from a donor with TTS. Iodine-123 meta-iodobenzylguanidine (123I-MIBG) scintigraphy results for evaluating sympathetic activity are presented. Case Summary: A 46-year-old woman underwent heart transplantation for dilated phase of hypertrophic cardiomyopathy following recurrent cerebral haemorrhage complications after left ventricular assist device therapy 2 years prior. The donor heart exhibited a transient mildly reduced left ventricular ejection fraction suggestive of TTS. Four years post-transplantation, she was admitted with difficulty breathing, and echocardiography showed decreased biventricular apical wall motion. During her treatment course, wall motion improved spontaneously, and giant negative T waves were observed on electrocardiography (ECG). Coronary computed tomography and endomyocardial biopsy findings were normal, and a diagnosis of TTS was made. Approximately 5 years post-transplantation, she was readmitted with difficulty breathing, and echocardiography showed akinesis of the mid-to-apical biventricular wall. Wall motion normalized within a few days, and ECG showed typical giant negative T waves, consistent with TTS. 123I-MIBG scintigraphy taken prior to discharge and 6 months later showed minimal myocardial uptake in the basal anterior wall, indicating insufficient sympathetic reinnervation. Discussion: Recurrent TTS in a denervated heart suggests the possibility of other underlying mechanisms besides cardiac sympathetic hyperactivity. This case highlights potential TTS development in transplant recipients from donors with TTS, underlining the need for close monitoring.
- Open Access
- 2 March 2025
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 12 (4) , 2441-2449
Electron Microscopic Findings Predict Clinical Outcomes in Patients with Non-Ischaemic Cardiomyopathy
Aims: Electron microscopy reveals microstructural alterations in cardiomyocyte nuclei and myofilaments in non-ischaemic cardiomyopathy (NICM), particularly in dilated cardiomyopathy (DCM). Nevertheless, the correlation between such observations and clinical outcomes, including prognosis and left ventricular reverse remodelling (LVRR), remains unclear. This study aimed to examine the association between electron microscopic findings and outcomes in patients with NICM. Methods: In this multicentre, prospective, observational study, 170 patients with NICM with reduced ejection fraction (EF) < 40%, scheduled for diagnostic endomyocardial biopsy and optimization of medical therapies, were enrolled. Electron microscopic findings of cardiomyocytes such as discontinuous or continuous nuclear envelopes and injured or preserved myofilaments were evaluated. Data on cardiac events (cardiac death or left ventricular assist device implantation) and LVRR, defined as achieving an EF > 35% with a 10% unit absolute increase, were collected 1 year post-biopsy. Results: A total of 148 patients were finally analysed. Discontinuous nuclear envelopes and myofilament injuries were observed in 17 (11%) and 46 (31%) patients with NICM, respectively. The incidence of cardiac events at 1 year did not differ between groups with discontinuous and continuous nuclear envelopes [12% vs. 6%, odds ratio (OR): 2.05, 95% confidential interval (CI): 0.40–10.6, P = 0.391], whereas the LVRR rate was significantly lower in the discontinuous group than in the continuous group (24% vs. 52%, OR: 0.29, 95% CI: 0.08–0.92, P = 0.036). The incidences of cardiac events and LVRR at 1 year differed between the injured and preserved myofilament groups (15% vs. 3%, OR: 6.64, 95% CI: 1.32–33.5, P = 0.022; 15% vs. 64%, OR: 0.10, 95% CI: 0.04–0.25, P < 0.001, respectively). These associations between electron microscopic findings and clinical outcomes persisted, even in patients who were finally diagnosed with DCM. Conclusions: Discontinuous nuclear envelopes were associated with a reduced LVRR rate, whereas injured myofilaments were correlated with higher 1 year cardiac events and a decreased LVRR. Evaluation of electron microscopic images in diagnostic endomyocardial biopsy can facilitate risk stratification of NICM or DCM with reduced EF.
- 2 March 2025
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 12 (4) , 2441-2449
Open AccessElectron Microscopic Findings Predict Clinical Outcomes in Patients with Non-Ischaemic Cardiomyopathy
Aims: Electron microscopy reveals microstructural alterations in cardiomyocyte nuclei and myofilaments in non-ischaemic cardiomyopathy (NICM), particularly in dilated cardiomyopathy (DCM). Nevertheless, the correlation between such observations and clinical outcomes, including prognosis and left ventricular reverse remodelling (LVRR), remains unclear. This study aimed to examine the association between electron microscopic findings and outcomes in patients with NICM. Methods: In this multicentre, prospective, observational study, 170 patients with NICM with reduced ejection fraction (EF) < 40%, scheduled for diagnostic endomyocardial biopsy and optimization of medical therapies, were enrolled. Electron microscopic findings of cardiomyocytes such as discontinuous or continuous nuclear envelopes and injured or preserved myofilaments were evaluated. Data on cardiac events (cardiac death or left ventricular assist device implantation) and LVRR, defined as achieving an EF > 35% with a 10% unit absolute increase, were collected 1 year post-biopsy. Results: A total of 148 patients were finally analysed. Discontinuous nuclear envelopes and myofilament injuries were observed in 17 (11%) and 46 (31%) patients with NICM, respectively. The incidence of cardiac events at 1 year did not differ between groups with discontinuous and continuous nuclear envelopes [12% vs. 6%, odds ratio (OR): 2.05, 95% confidential interval (CI): 0.40–10.6, P = 0.391], whereas the LVRR rate was significantly lower in the discontinuous group than in the continuous group (24% vs. 52%, OR: 0.29, 95% CI: 0.08–0.92, P = 0.036). The incidences of cardiac events and LVRR at 1 year differed between the injured and preserved myofilament groups (15% vs. 3%, OR: 6.64, 95% CI: 1.32–33.5, P = 0.022; 15% vs. 64%, OR: 0.10, 95% CI: 0.04–0.25, P < 0.001, respectively). These associations between electron microscopic findings and clinical outcomes persisted, even in patients who were finally diagnosed with DCM. Conclusions: Discontinuous nuclear envelopes were associated with a reduced LVRR rate, whereas injured myofilaments were correlated with higher 1 year cardiac events and a decreased LVRR. Evaluation of electron microscopic images in diagnostic endomyocardial biopsy can facilitate risk stratification of NICM or DCM with reduced EF.
- Open Access
- 1 January 2025
- Published by Wiley in Case Reports in Cardiology
- Vol. 2025 (1) , 1350557
Fulminant Cardiac Sarcoidosis Successfully Treated With Aggressive Immunosuppressive Therapy
Background: The clinical course of cardiac sarcoidosis is typically subacute, and fulminant cases requiring mechanical circulatory support are rare. Here, we report the case of a patient with pathologically diagnosed cardiac sarcoidosis who presented with fulminant myocarditis and whose cardiac function was improved by aggressive immunosuppressive therapy based on the treatment of giant cell myocarditis. Case Presentation: A 55‐year‐old woman presented with progressive dyspnoea and nausea that persisted for 1 month and was eventually diagnosed with acute heart failure. Echocardiography showed a reduced left ventricular ejection fraction with thinning of the basal septal wall. During hospitalisation, she experienced ventricular tachycardia and fibrillation attacks, and bradycardia due to a complete atrioventricular block and sinus dysfunction was observed after starting amiodarone. Subsequently, she underwent intra‐aortic balloon pump insertion in addition to inotropic agent administration; however, venoarterial extracorporeal membrane oxygenation and Impella 5.0 were needed because biventricular dysfunction progressed. We diagnosed our patient with cardiac sarcoidosis based on the pathological findings revealing inflammatory cell infiltration, including giant cells with extensive fibrosis and granulomas. However, the possibility of giant cell myocarditis could not be ruled out because of the fulminant clinical course; therefore, aggressive immunosuppressive therapy with corticosteroids and cyclosporine was started. Her cardiac function improved, and all mechanical circulatory support and inotropic agents were discontinued. Conclusion: Cardiac sarcoidosis is difficult to differentiate from giant cell myocarditis because they have many similarities in terms of myocardial histopathology and clinical manifestations. While whether the two diagnoses are parts of a single‐disease continuum remains debatable, aggressive combination immunosuppressive therapy may contribute to favourable outcomes.
- 1 January 2025
- Published by Wiley in Case Reports in Cardiology
- Vol. 2025 (1) , 1350557
Open AccessFulminant Cardiac Sarcoidosis Successfully Treated With Aggressive Immunosuppressive Therapy
Background: The clinical course of cardiac sarcoidosis is typically subacute, and fulminant cases requiring mechanical circulatory support are rare. Here, we report the case of a patient with pathologically diagnosed cardiac sarcoidosis who presented with fulminant myocarditis and whose cardiac function was improved by aggressive immunosuppressive therapy based on the treatment of giant cell myocarditis. Case Presentation: A 55‐year‐old woman presented with progressive dyspnoea and nausea that persisted for 1 month and was eventually diagnosed with acute heart failure. Echocardiography showed a reduced left ventricular ejection fraction with thinning of the basal septal wall. During hospitalisation, she experienced ventricular tachycardia and fibrillation attacks, and bradycardia due to a complete atrioventricular block and sinus dysfunction was observed after starting amiodarone. Subsequently, she underwent intra‐aortic balloon pump insertion in addition to inotropic agent administration; however, venoarterial extracorporeal membrane oxygenation and Impella 5.0 were needed because biventricular dysfunction progressed. We diagnosed our patient with cardiac sarcoidosis based on the pathological findings revealing inflammatory cell infiltration, including giant cells with extensive fibrosis and granulomas. However, the possibility of giant cell myocarditis could not be ruled out because of the fulminant clinical course; therefore, aggressive immunosuppressive therapy with corticosteroids and cyclosporine was started. Her cardiac function improved, and all mechanical circulatory support and inotropic agents were discontinued. Conclusion: Cardiac sarcoidosis is difficult to differentiate from giant cell myocarditis because they have many similarities in terms of myocardial histopathology and clinical manifestations. While whether the two diagnoses are parts of a single‐disease continuum remains debatable, aggressive combination immunosuppressive therapy may contribute to favourable outcomes.
- Open Access
- 26 April 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (5) , 555
Switching from Beraprost to Selexipag in the Treatment of Pulmonary Arterial Hypertension: Insights from a Phase IV Study of the Japanese Registry (The EXCEL Study: EXChange from bEraprost to seLexipag Study)
Pulmonary arterial hypertension (PAH) remains a significant challenge in cardiology, necessitating advancements in treatment strategies. This study explores the safety and efficacy of transitioning patients from beraprost to selexipag, a novel selective prostacyclin receptor agonist, within a Japanese cohort. Employing a multicenter, open-label, prospective design, 25 PAH patients inadequately managed on beraprost were switched to selexipag. Key inclusion criteria included ongoing beraprost therapy for ≥3 months, a diagnosis of PAH confirmed by mean pulmonary artery pressure (mPAP) ≥ 25 mmHg, and current treatment with endothelin receptor antagonists and/or phosphodiesterase type 5 inhibitors. Outcomes assessed were changes in hemodynamic parameters (mPAP, cardiac index, pulmonary vascular resistance) and the 6 min walk distance (6-MWD) over 3–6 months. The study found no statistically significant changes in these parameters post-switch. However, a subset of patients, defined as responders, demonstrated improvements in all measured hemodynamic parameters, suggesting a potential benefit in carefully selected patients. The transition was generally well-tolerated with no serious adverse events reported. This investigation underscores the importance of personalized treatment strategies in PAH, highlighting that certain patients may benefit from switching to selexipag, particularly those previously on higher doses of beraprost. Further research is needed to elucidate the predictors of positive response to selexipag and optimize treatment regimens for this complex condition.
- 26 April 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (5) , 555
Open AccessSwitching from Beraprost to Selexipag in the Treatment of Pulmonary Arterial Hypertension: Insights from a Phase IV Study of the Japanese Registry (The EXCEL Study: EXChange from bEraprost to seLexipag Study)
Pulmonary arterial hypertension (PAH) remains a significant challenge in cardiology, necessitating advancements in treatment strategies. This study explores the safety and efficacy of transitioning patients from beraprost to selexipag, a novel selective prostacyclin receptor agonist, within a Japanese cohort. Employing a multicenter, open-label, prospective design, 25 PAH patients inadequately managed on beraprost were switched to selexipag. Key inclusion criteria included ongoing beraprost therapy for ≥3 months, a diagnosis of PAH confirmed by mean pulmonary artery pressure (mPAP) ≥ 25 mmHg, and current treatment with endothelin receptor antagonists and/or phosphodiesterase type 5 inhibitors. Outcomes assessed were changes in hemodynamic parameters (mPAP, cardiac index, pulmonary vascular resistance) and the 6 min walk distance (6-MWD) over 3–6 months. The study found no statistically significant changes in these parameters post-switch. However, a subset of patients, defined as responders, demonstrated improvements in all measured hemodynamic parameters, suggesting a potential benefit in carefully selected patients. The transition was generally well-tolerated with no serious adverse events reported. This investigation underscores the importance of personalized treatment strategies in PAH, highlighting that certain patients may benefit from switching to selexipag, particularly those previously on higher doses of beraprost. Further research is needed to elucidate the predictors of positive response to selexipag and optimize treatment regimens for this complex condition.